Simulations Plus, Inc. – Consensus Indicates Potential 48.7% Upside

Broker Ratings

Simulations Plus, Inc. which can be found using ticker (SLP) now have 4 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price High/Low ranges between 70 and 44 with the average target price sitting at $58.75. Given that the stocks previous close was at $39.52 this now indicates there is a potential upside of 48.7%. The 50 day moving average now sits at $39.27 while the 200 day moving average is $47.28. The market capitalization for the company is $851m. Visit the company website at:

The potential market cap would be $1,265m based on the market consensus.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems toxicology software; NAFLDsym; IPFsym; RENAsym; IPFsym; and MITOsym. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was incorporated in 1996 and is headquartered in Lancaster, California.

The company has a dividend yield of 0.61% with the ex dividend date set at 27-1-2023 (DMY).

Other points of data to note are a P/E ratio of 82.08, revenue per share of 2.64 and a 4.04% return on assets.

Find more news, interviews, share price & company profile here for:

    Good news travels fast (but only if you make that happen). Share on:

    Forum friendly shortlink:

      AIM All Share Index